MALVERN, Pa., July 27, 2015 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the Honorable Juan R. Sanchez has denied MedTel24’s Motion for Relief From Consent Judgment, upholding a prior Judgment from January 2014 that stated MedTel24’s use or sale of certain Heart Monitoring software infringes upon BioTelemetry patents.
In 2012, CardioNet, a BioTelemetry subsidiary, filed suit against MedTel24, Inc. and other Companies in the United States District Court for the Eastern District of Pennsylvania for patent infringement. CardioNet sought an injunction against each defendant, as well as monetary damages. The defendants asserted counterclaims alleging the patents in the suit were invalid and not infringed.
The litigation concluded in early 2014 when the Court entered a Consent Judgment declaring all five CardioNet patents valid, enforceable and infringed upon by the defendants. The Consent Judgment also declared that all defendants are permanently enjoined from further infringement and are required to turn over all existing inventory of the Heartrak ECAT system to the Company.
The Court’s order comes in response to the attempt by MedTel24 to challenge the Consent Judgment. MedTel24 was the only defendant to challenge the original Judgement.
In finding for BioTelemetry, Judge Sanchez specifically upheld the validity of the Consent Judgement which provided that MedTel24’s “making, using, offering to sell or selling in the United States the accused Heartrack ECAT system, including (i) a Heartrack ECAT Monitor; (ii) a Heartrack ECAT communicator; and (iii) CardioStation or eCardioStation software infringes the five patents-in-suit.”
Joseph Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “This decision further highlights the strength of our patent portfolio. We are pleased with the Court’s ruling as it is evidence of the impact of our patent defense strategy. On the heels of this victory, the Company will continue to vigorously protect our intellectual property, including taking action against any parties that employ our products without consent.”
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.biotelinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, our ability to successfully integrate the Mednet, Biomedical Systems and Radcore businesses into our business and the effect such acquisitions will have on our results of operation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: BioTelemetry, Inc. Heather C. Getz Investor Relations 800-908-7103 email@example.com